Conjupro Biotherapeutics, Inc.

CONJUPRO BIOTHERAPEUTICS, INC. is a biopharmaceutical company headquartered in Princeton, New Jersey, founded in 2017. It operates as a subsidiary of CSPC Pharmaceutical Group Limited ("CSPC"), a large Chinese pharmaceutical company listed on the Hong Kong Stock Exchange (1093.HK). The company employs between 10 and 50 individuals.

Conjupro Biotherapeutics focuses on preclinical and clinical research and development, providing diversified R&D solutions. Its primary areas of therapeutic focus include oncology, cardiology, and central nervous system (CNS) diseases, with the goal of developing new medicines. The company also engages in drug discovery and clinical development, recently celebrating its first New Drug Approval in the USA.

According to the authoritative case data, CONJUPRO BIOTHERAPEUTICS, INC. has been involved in one tracked patent litigation case as a plaintiff and zero as a defendant. This indicates an active posture in managing its intellectual property. The single tracked case, CONJUPRO BIOTHERAPEUTICS, INC. v. Ascletis Pharma China Co Ltd, is a Post-Grant Review (PGR) proceeding initiated at the Patent Trial and Appeal Board (PTAB) on June 20, 2025. In this proceeding, Conjupro is challenging a patent held by Ascletis Pharma China Co Ltd, which is typical for an operating company actively navigating the patent landscape to protect its market interests or clear potential obstacles for its products.